Introduction
The vascular endothelial growth factor (VEGF) family of proteins modulates many endothelial cell functions, especially involving vasculogenesis and angiogenesis (1) . VEGF-A was the first-described member of the VEGF family; VEGF-A induces angiogenesis by activating the related tyrosine kinase receptors, VEGF-R1 and VEGF-R2, on endothelial cells (1, 2) . Whereas VEGF-A plays a paramount role in tumor angiogenesis, VEGF-C has been characterized as an essential lymphangiogenic factor that promotes cancer metastasis (3) (4) (5) . VEGF-C is a ligand for both VEGF-R3 and VEGF-R2 but has a high affinity for VEGF-R3 (2) . VEGF-R3 is expressed mainly on lymphatic endothelial cells. VEGF-C causes phosphorylation of VEGF-R3, leading to phosphatidylinositol 3-kinase-dependent Akt activation and protein kinase C-dependent activation of the p42/p44 mitogen-activated protein kinase (MAPK) pathway, thus protecting lymphatic endothelial cells from apoptosis and stimulating proliferation and migration in vitro (6) . Moreover, it has recently been shown that VEGF-R3 may also drive angiogenesis (7, 8) . The angiogenic VEGF-R3 signal is predominantly active in the setting of angiogenic invasion of tissues, such as occurs with tumors. VEGF-R3 potentiates the effects of VEGF-R2 and may sustain angiogenesis, even in the presence of VEGF-R2 inhibitors (8) . These studies highlighted the significant biological role of the VEGF-C/VEGF-R3 axis in vascular endothelial cells.
Numerous studies have demonstrated that VEGF-R3 is also expressed in a variety of human malignancies (9-13), although there is disagreement regarding the expression of VEGF-R3 in tumor cells of solid malignancies (14, 15) . The function and molecular mechanism of the VEGF-C/VEGF-R3 axis in cancer cells, however, is not well understood. Previous studies have demonstrated that tyrosine phosphorylation of VEGF-R3 in cancer cells stimulates cell proliferation in Kaposi's sarcoma, malignant mesothelioma, leukemia and gastric cancer (12, (16) (17) (18) . We and others have shown that activation of VEGF-C/VEGF-R3 signaling in cancer cells enhances cell mobility and invasiveness and contributes to the promotion of cancer cell metastasis (11, 16, 19) . These findings, taken together, indicate the importance of VEGF-C signaling in tumor biology by acting directly on tumor cells.
The expression of VEGF-R3 and its ligand, VEGF-C, in bone marrow (BM) specimens from patients with acute myeloid leukemia (AML) has been surveyed previously. Fielder et al. (20) were the first to describe increased expression of VEGF-R3 and VEGF-C in BM biopsies from AML patients when compared with normal volunteers. In another study, the expression of VEGF-C/VEGF-R3 in BM was significantly higher in AML patients than in controls by using immunohistochemical staining (21) . Furthermore, a recent study showed that higher endogenous VEGF-C levels of AML cells are related to decreased in vitro and in vivo responsiveness to chemotherapy (22) ; an effect that may result from inhibition of apoptosis by increasing Bcl-2:Bax ratios by the VEGF-C/VEGF-R3 pathway (18) . Thus, a functional VEGF-C/VEGF-R3 system may exist in leukemia.
BM neoangiogenesis plays a crucial pathogenic and possible prognostic role in AML and depends on the interplay of members of the VEGF and angiopoietin families (23) . The VEGF-C/VEGF-R3 axis has been proven in the regulation of solid tumors angiogenesis (7). However, information concerning the role of VEGF-C/VEGF-R3 in non-solid tumors angiogenesis is still lacking. The present study was undertaken to investigate the extent of angiogenesis induced by VEGF-C in leukemic cells. We have shown that VEGF-C activates tumor angiogenesis in the AML cell line, THP-1, via induction of COX-2 expression. We have also unveiled the molecular mechanism for the transcriptional regulation of COX-2 by VEGF-C.
Materials and methods

Primary cells and cell lines
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord as described by Jaffe et al. (24) . HUVECs were cultured in M199
Abbreviations: AP-1, activator protein 1; AML, acute myeloid leukemia.BM, bone marrow; ChIP, chromatin immunoprecipitation; CM, conditioned medium; COX-2, cyclooxygenase-2; CRE, cyclic adenosine 3#,5#-monophosphateresponse element; ERK1/2, extracellular signal-related kinase 1/2; HUVEC, human umbilical vein endothelial cell; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; mRNA, messenger RNA; PCR, polymerase chain reaction; PGE 2 , prostaglandin E2; VEGF, vascular endothelial growth factor; NF-jB, nuclear factor-jB. Antibodies and reagents VEGF-C, VEGF-C (Cys 156 Ser), VEGF-A 165 and VEGF-R3/Fc were purchased from R&D Systems (Minneapolis, MN). NS 398, indomethacin, PD 98059, SB203580 and pyrrolidine dithiocarbamate (PDTC) were purchased from Calbiochem-Novabiochem (La Jolla, CA). SP 600125 and mithramycin were obtained from Sigma-Aldrich (St. Louis, MO). SU 11248 and Bay 439006 were purchased from Pfizer (New York, NY) and Bayer (St. Gallen, Switzerland), respectively. The following primary antibodies were used: COX-2 (Transduction Laboratories); proliferating cell nuclear antigen (PCNA) (Upstate Biotechnology, Lake Placid, NY); VEGF-C (R&D Systems); p-JNK, p-p38 MAPK, c-Jun, c-Fos (Cell Signaling Technology, Beverly, MA); pERK1/2, extracellular signal-related kinase 1/2 (ERK1/2), p38 MAPK, c-Jun N-terminal kinase (JNK), a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA).
COX-2-specific RNA interference and dominant-negative JNK1 mutant (JNK1-APF) The target sequence for the COX-2 small interfering RNA (siRNA) was bases 291-313 of NM000963.1 (5#-aactgctcaacaccggaattttt-3#) following the description by Denkert et al. (25) . The pRNA-U6/neo (GenScript Corporation, Piscataway, NJ) is a siRNA expression vector with neomycin as the selection marker. We constructed a constitutively expressed vector, pRNA-U6/COX-2, which carries the COX-2 siRNA sequence under the control of the U6 promoter. The pcDNA3-FLAG-JNK1 (APF) vector contains a catalytically inactive dominant-negative mutant of JNK1 with an N-terminal FLAG tag (26) , which was kindly provided by Dr C.-H.Lin (Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan). The THP-1 cells were transiently transfected with pcDNA3, pcDNA3-FLAG-JNK1 (APF), pRNA-U6/neo or pRNA-U6/COX-2 for 6 h by using metafectene (Biontex, Martinsried, Germany) following the manufacturer's protocol. The effects of COX-2 siRNA or dominant-negative mutant of JNK1 on COX-2 protein expression were confirmed by western blotting.
Preparation of conditioned medium A total of 2 Â 10 6 THP-1 cells were serum-starved overnight and treated with VEGF-C (100 ng/ml) for 48 h. To assay the effects of various inhibitors, cells were pretreated with inhibitors for 40 min prior to the VEGF-C treatment. To assay the effect of COX-2-specific siRNA, pRNA-U6/COX-2 was transiently transfected for 6 h and then treated with VEGF-C. The culture supernatants were collected and immediately used for migration and tube formation assays or stored at À70°C until use. For plug assay, conditioned medium (CM) were centrifuged at 12 500g for 30 min using Microcon YM-3 centrifugal filter devices (Millipore Corporation, Bedford, MA) (with the cutoff of molecules smaller than 3000 Da), to obtain a 10-fold concentrated CM.
Prostaglandin E 2 assay
The prostaglandin E 2 (PGE 2 ) level was assessed in the CM of VEGF-C-treated THP-1 cells, using a commercially available ELISA kit (Cayman Chemical, Ann Arbor, MI). The measurement was carried out according to the manufacturer's instructions, and each experiment was repeated in triplicate.
Matrigel blood plug in vivo assay
Matrigel blood plug assay was performed as described previously (27) . Briefly, C57BL/6 mice (three per group) were subcutaneously injected with 50 ll CM from THP-1, with different treatment conditions, together with 450 ll Matrigel (growth factor reduced) (BD Biosciences, Bedford, MA) and 40 U heparin/ml at 4°C. Mice were euthanized 7 days postinjection; gels were recovered and processed for further studies. Neovessels was quantified by Drabkin's method, measuring hemoglobin of the plug with the Drabkin reagent kit 525 (Sigma, St Louis, MI).
In vitro capillary tube formation on Matrigel
The HUVECs (1 Â 10 4 cells per well) were seeded on top of Matrigel (50 ll per well) coated 96-well (5 mm) tissue culture dishes in 0.3 ml culture medium containing 150 ll M199 with 2% fetal calf serum (Gibco BRL, Rockville, MD) and 150 ll CM. Tube formation was quantified, by counting the number of tube-like structures formed by connecting endothelial cells in 9.7 mm 2 microscopic fields. The assay was performed in triplicates.
Endothelial cell migration assay HUVECs (7 Â 10 4 cells per well) were suspended in 200 ll M199 medium with 1% fetal calf serum and loaded into the upper chamber of a transwell cluster plate. A 0.6 ml culture medium containing 300 ll M199 with 2% fetal calf serum and 300 ll CM was added to the lower wells of the chamber. After incubation for 8 h, cells that migrated onto the lower side of the membrane were stained with crystal violet (Sigma). The stained cells in each well were photographed (with a Â200 magnification) and counted.
COX-2 promoter activity assay
The COX-2 promoter constructs [À327/þ59, NF-kB binding site mutated (jBM), NF-IL6 binding site mutated (ILM) and CRE binding site mutated (CRM)] were generated as described previously (28) . The pRL-TK Renilla control vector was purchased from Promega (Madison, WI). Cells were seeded at 2 Â 10 6 cells per well in 6-well culture plates and co-transfected with 1 lg COX-2 promoter construct and 0.5 lg pRL-TK Renilla control vector using metafectene (Biontex) according to the manufacturer's protocol. After 5 h, medium containing 10% fetal bovine serum was added and cells were incubated overnight. Subsequently, cells were serum-starved overnight and then treated with VEGF-C for 24 h. Firefly and Renilla luciferase activity was measured using the dual-luciferase reporter assay kit (Promega). Firefly luciferase activity was adjusted to Renilla luciferase activity as a control for variations in cell viability and transfection efficiency.
Reverse transcription-polymerase chain reaction Messenger RNAs (mRNAs) were isolated and amplified as previously been described (27) . The primers sequences are shown as supplementary data (supplementary Table 1 is available at Carcinogenesis Online).
Nuclear and cytosolic protein extraction For nuclear and cytosolic protein extraction, the protein extracts were prepared from VEGF-C-treated THP-1 cells using the NE-PER Cytoplasmic and Nuclear Protein extraction kit (Pierce Biotechnology, Rockford, IL).
Western blot analysis
Protein lysates were prepared as previously been described (27) . Western blotting was performed with primary antibodies for COX-2, p-JNK, p-p38 MAPK, pERK1/2, JNK, p38 MAPK, ERK1/2, c-Jun, c-Fos, PCNA or a-tubulin.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) assay was carried out as described previously (29) with minor modification. In brief, THP-1 cells were treated with 1% formaldehyde for 15 min. The cross-linked chromatin was then prepared and sonicated to an average size of 300-400 bp before being immunoprecipitated with antibodies specific to c-Jun, c-Fos or control rabbit IgG at 4°C overnight. After reversal of cross-linking, the immunoprecipitated chromatin was polymerase chain reaction (PCR) amplified with the following primers specific for the COX-2 promoter: F186-1, CTGGGTTTCCGATTTTCTCA and R49, GAGTTCCTGGACGTGCTCCT. The resulting PCR products were separated by agarose gel electrophoresis.
Immunohistochemical staining BM samples were fixed in paraformaldehyde, decalcified with ethylenediaminetetraacetic acid and embedded in paraffin. Serial sections (4 lM thick) of each sample were processed immunohistochemically for the expression of VEGF-C and COX-2 with anti-human VEGF-C and anti-human COX-1 antibodies. Non-immune mouse IgG or rabbit IgG (Santa Cruz Biotechnology) were used as negative control. Immunohistochemical staining was detected using streptavidin-biotin peroxidase complex method by DAB Peroxidase Substrate Kit (SK-4100; Vector Laboratories, Burlingame, CA).
Statistical Analysis
Differences between the means of unpaired samples were evaluated by the Student's t-test using the SigmaPlot and SigmaStats program. P , 0.05 was considered statistically significant.
Results
COX-2 mediated VEGF-C-induced angiogenesis
The effect of VEGF-C on angiogenesis in vitro was initially examined by migration and tube formation of HUVECs cultured with CM. The CM obtained from the VEGF-C-treated human AML cell line, THP-1, showed significant increased cell migration and tube formation in the microscopic field as compared with controls (P , 0.01; supplementary Figure 1A and B are available at Carcinogenesis Online). We next assessed the effect of VEGF-C on the induction of angiogenesis in vivo using the Matrigel plug assay. Matrigel plugs containing 0.1% bovine serum albumin (vehicle control), VEGF-A (100 ng/ml; positive control), VEGF-C (100 ng/ml) or CM from VEGF-C-treated THP-1 were injected subcutaneously into mice near the abdominal midline. Seven days later, upon visual examination, substantial vasculature was evident in plugs embedded with VEGF-A or CM, even with hemorrhaging in the plugs, as compared with vehicle controls ( Figure 1A ). CM from VEGF-C-treated THP-1 induced a significant increase in the hemoglobin level relative to the control group (P , 0.01), whereas VEGF-C alone only slightly increased the hemoglobin level as compared with controls ( Figure 1A) . Further, VEGF-C at a dose 100 ng/ml did not cause HUVECs proliferation and CM immunodepleted of VEGF-C showed a similar angiogenic effect (supplementary Figure 1C and D are available at Carcinogenesis Online).
These results support an indirect tumor angiogenic role of VEGF-C for leukemic cells. We therefore screened angiogenic factors that mediated VEGF-C-induced angiogenesis. Among angiogenic factors that essentially regulate vascularity in the BM of leukemia (30, 31) , Fig. 1 . COX-2 mediates the VEGF-C-induced angiogenesis. (A) Matrigel plugs containing VEGF-A (100 ng/ml; positive control), VEGF-C (100 ng/ml) or ten times concentrated conditioned medium (CM) collected from VEGF-C (100 ng/ml) or bovine serum albumin (0.1%; negative control) treated THP-1 cells, were implanted into C57BL/6 mice (three per group). The mice were euthanized 7 days after implantation. The gross appearance of the plugs was photographed (upper panel). The blood plugs were extracted and quantitation of hemoglobin was performed using the Drabkin's method. The mean amount of hemoglobin was calculated. Student's t-test was used for comparison (lower panel).
ÃÃ P , 0.01 as compared with the vehicle control group. (B) Angiogenic factor mRNA screen from THP-1 treated with VEGF-C (100 ng/ml) for 4 and 8 h (n 5 2). TGF-a: Transforming growth factor-a; TGF-b: Transforming growth factor-b; HGF: Hepatocyte growth factor; EGF: Epidermal growth factor; bFGF: Basic fibroblast growth factor; PDGF: Platelet-derived growth factor. (C) THP-1 cells were pretreated with 10 lM NS 398 or indomethacin for 30 min before incubation with VEGF-C (100 ng/ml) for 48 h. The CM was collected and concentrated for the Matrigel blood plug assay in C57BL/6 mice (three per group). The mean amount of hemoglobin in blood plugs was calculated.
ÃÃ P , 0.01 as compared with the VEGF-C treatment group. (D and E) A total of 2 Â 10 6 THP-1 cells were transiently transfected with a different dosage of COX-2-specific siRNA (pRNA-U6/ COX-2) or control siRNA (pRNA-U6/neo) for 6 h, followed by VEGF-C treatment for 48 h. COX-2 protein levels in THP-1 were reduced by a different dosage of COX-2-specific siRNA transfection (D, upper panel) . The CM was collected for HUVECs migration assay (D) or tube formation assay (E) after siRNA transfection. Columns, means of three independent experiments; bars, ±SE.
ÃÃ P , 0.01 as compared with the VEGF-C treatment group.
VEGF-C promotes angiogenesis in leukemic cells
COX-2 mRNA was selectively induced upon VEGF-C treatment ( Figure 1B) . To verify the role of COX-2 in VEGF-C-mediated angiogenesis, the COX-2 inhibitors, NS 398 and indomethacin, were used. By using the in vivo Matrigel plug assay ( Figure 1C ) and the in vitro HUVECs migration and tube formation assays (supplementary Figures 2A and B are available at Carcinogenesis Online), the angiogenic effects induced by VEGF-C were substantially inhibited by pretreatment of THP-1 cells with NS 398 or indomethacin. To exclude the direct inhibitory effect on HUVECs of residual NS 398 or indomethacin in the CM, COX-2-specific siRNA was used. In THP-1 cells, the VEGF-C-induced COX-2 expression was reduced by 60-70% by transient transfection with COX-2-specific siRNA. In effect, knockdown of the COX-2 gene significantly suppressed VEGF-C-induced angiogenesis, as evaluated by HUVECs migration or tube formation assays ( Figure 1D and E).
VEGF-C upregulates COX-2 expression and PGE 2 release via VEGF-R3 activation in leukemic cells Exposure of THP-1 cells to VEGF-C (100 ng/ml) resulted in a timedependent increase in COX-2 mRNA and protein expression, with a maximal effect at 24 and 48 h, respectively (Figure 2A ). Treatment with VEGF-C (50-200 ng/ml; for 8 or 48 h) also induced expression of COX-2 mRNA and protein in a concentration-dependent manner ( Figure 2B ). To exclude the possibility that our results were cell-type dependent, we used two other AML cell lines (HL-60 and U937) that expressed both VEGF-R2 and VEGF-R3. As expected, exposure of HL-60 or U937 cells to VEGF-C (100 ng/ml) also resulted in COX-2 induction in protein and mRNA levels (supplementary Figure 3A is available at Carcinogenesis Online). These results demonstrated that VEGF-C induced COX-2 expression in subsets of leukemia. Moreover, PGE 2 , a downstream product regulated by COX-2 that is essentially responsible for angiogenesis (32) , was also induced by VEGF-C (100 ng/ml) in a time-dependent manner ( Figure 2C ). The biologic activities of VEGF-C are mediated through binding to the membrane-bound receptors, VEGF-R3 and VEGF-R2, on target cells (18, 33) . Exposure of THP-1 to a VEGF-R3-selective mutant of VEGF-C (Cys156Ser mutation) resulted in a significant induction of COX-2 ( Figure 2D ). Pretreatment of THP-1 cells with recombinant soluble VEGF-R3/Fc attenuated VEGF-C-induced COX-2 expression in a concentration-dependent manner ( Figure 2D ). These results indicated that VEGF-R3 activation plays a major role in VEGF-C-induced COX-2 expression in AML cells. In parallel experiments, treatment with VEGF-A (50 ng/ml), which activates both VEGF-R1 and VEGF-R2, caused COX-2 expression in AML cells, but to a lesser extent (supplementary Figure 3B is available at Carcinogenesis Online).
Signaling through the JNK pathway is essential for COX-2 induction by VEGF-C The VEGF-C-VEGF-R3 interaction has been shown to activate several signaling pathways in endothelial cells, including phosphatidylinositol 3-kinase/Akt, ERK1/2 kinase and JNK1/2 (34). Treatment of THP-1 cells with VEGF-C for various time intervals also resulted in ERK1/2 and JNK1/2 activation in a time-dependent manner and with a maximal response at 0.5 and 1 h, respectively, after treatment ( Figure 3A) . In order to determine whether ERK1/2 and JNK1/2 activation is involved in the signal transduction pathway leading to COX-2 expression caused by VEGF-C, the MAPK kinase inhibitor, PD 98059, and the JNK1/2 inhibitor, SP 600125, were used. Pretreatment of cells for 30 min with SP 600125 (3 and 10 lM) attenuated VEGF-C-induced COX-2 expression in a concentration-dependent manner, whereas PD 98059, at a concentration up to 30 lM, had no effect. To further confirm the role of JNK1/2 in VEGF-C-induced COX-2 expression 
Activator protein 1 is an important transcription factor for VEGF-Cinduced COX-2 expression
The COX-2 promoter is under strict control through a tight regulatory network and is known to contain many transacting elements that bind a variety of transcription factors, including Sp1, nuclear factor-jB (NF-jB), nuclear factor-IL6 (NF-IL6) and cyclic adenosine 3#,5#-monophosphate-response element binding protein/activator protein 1 (AP-1) that regulate the promoter activity in many cell types under various conditions (35) . To test whether some of these transcription factors are involved in VEGF-C-induced COX-2 expression in THP-1 cells, we used chemical inhibitors against Sp1 (mithramycin), NF-jB (PDTC) and AP-1 (JNK inhibitor SP 600125). Of these inhibitors, only SP 600125 was capable of suppressing VEGF-C-induced COX-2 expression ( Figure 4A ). We also found the VEGF-C induced the AP-1 subunit, c-jun, but not c-fos, nuclear translocation in a time-dependent manner ( Figure 4B ), and this effect was significantly inhibited by SP 600125, but not PD 98059 or SB 203580 ( Figure 4C ). Overall, these results suggest that the JNK pathway and the transcription factor AP-1 are critical for VEGF-C-induced COX-2 expression.
Cyclic adenosine 3#,5#-monophosphate-response element is an important transcription regulatory element for VEGF-C-induced COX-2 expression We further performed luciferase assays with plasmids containing partial COX-2 promoter sequences (À327/þ59, jBM, ILM and CRM; Figure 4D ). The mutant constructs, jBM, ILM and CRM, indicated the consensus sequences for NF-jB (À233/À214), NF-IL6 (À132/À124) and cyclic adenosine 3#,5#-monophosphateresponse element (CRE) (À59/À53) in the proximal 5#-flanking region of the COX-2 gene were site-specific mutants ( Figure 4D ) in order to analyze their roles in controlling the expression of the COX-2 gene. We observed that CRE was a critical regulatory motif for VEGF-C-induced expression of COX-2 in THP-1 cells. Cells transfected with plasmids harboring mutant CRE sequences showed significantly lower inductions of luciferase activity in response to VEGF-C treatment ( Figure 4D ). In contrast, mutation of the NF-jB site or NF-IL6 site had no effect on VEGF-C responsiveness ( Figure 4D ). These data indicate that CRE is a critical regulatory motif for VEGF-C-induced COX-2 expression because AP-1 binding to the CRE region has been previously reported to regulate COX-2 promoter activity (36, 37) . The binding of c-Jun or c-Fos to the COX-2 promoter CRE region was then evaluated by the ChIP assay. Sonicated chromatin was precipitated with antibodies against c-Jun or c-Fos. Non-immune rabbit IgG was used as a control. The region of the COX-2 promoter pulled down by immunoprecipitation was identified by PCR using two COX-2-specific primers. The same sonicated lysates on ChIP was also checked by PCR. In contrast to c-Fos, binding of c-Jun to the CRE/E-box containing COX-2 promoter was enhanced in cells treated with VEGF-C in a time-dependent manner, whereas non-immune rabbit IgG failed to precipitate this COX-2 promoter region ( Figure 4E ). These results suggest that the binding of c-Jun to the COX-2 promoter CRE region was required for VEGF-C-induced expression of COX-2 in THP-1 cells.
COX-2 expression correlated with VEGF-C level in AML
To ascertain the relationship between VEGF-C and COX-2 in clinical specimens, BM specimens randomly selected from patients with 
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AML were immunohistochemically stained with antibodies specific to VEGF-C and COX-2. The representative immunohistochemical staining patterns of COX-2 and VEGF-C from consecutive serial sections were near identical in BM specimens, implying highly correlated expression ( Figure 5 and supplementary Figure 5 is available at Carcinogenesis Online). The relationships between the level of VEGF-C and COX-2 expression in BM specimens of AML patients are summarized in Table I . Notably, the level of VEGF-C expression in specimens was significantly associated with the expression of COX-2 (tested by Spearman's non-parametric correlation test, correlation coefficient q 5 0.55, P 5 0.0005; Table I ).
Discussion
The specific contribution of VEGF-C to the process of liquid tumor angiogenesis has not been properly defined. VEGF-C is capable of signaling through both VEGF-R2 and VEGF-R3 and induces endothelial proliferation and migration (33) ; however, the angiogenic effect of VEGF-C in liquid tumor may primarily derive from an indirect effect. In this report, we demonstrate that VEGF-C may promote leukemic angiogenesis by inducing COX-2 expression in subsets of leukemias. Our studies showed that VEGF-R3 is functional on leukemic cells and essentially conveys signals regulating COX-2 expression. The expression of VEGF-R3 has been identified in over one-third of human primary acute leukemias screened (20) . Our results present a close correlation of VEGF-C and COX-2 expression in the BM biopsies from acute leukemia patients. These results, taken together, extend our understanding of the role of VEGF-C/VEGF-R3 signaling in leukemic cells and highlight its potential as a therapeutic target for acute leukemia.
Prostanoids are critical for numerous biologic processes, including inflammation, angiogenesis and immunologic function. COX-2 catalyzes one of the rate-limiting steps in prostanoid biosynthesis (32) . Of importance, there is ample genetic and pharmacologic evidence to implicate COX-2 in tumorigenesis, including colon, breast and lung cancers, and leukemia (38) . Hematologic malignancies often highly express COX-2, which enhances survival and proliferation of malignant cells, while negatively influencing anti-tumor immunity. These findings are in line with accumulating clinical evidence showing that the expression of COX-2 correlates with poor patient prognosis in hematologic malignancies (39) . Here, we demonstrated that VEGF-C induced angiogenesis in vitro and in vivo through the . VEGF-C-stimulated luciferase activity was almost completely abolished by site-directed mutagenesis of cyclic adenosine 3#,5#-monophosphate-response element binding protein/AP-1-binding sites, but not NF-jB or NF-IL6 site mutation. The COX-2 promoter activities were calculated as the firefly:renilla luciferase activity ratios and normalized to the vehicle control (0.1% bovine serum albumin). Data are shown as the mean ± SE of three independent experiments. (E) THP-1 cells were treated with 100 ng/ml VEGF-C for the indicated times and subjected to a ChIP assay, as described in the Materials and Methods.
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COX-2-prostanoid pathway. Antagonists of PGE 2 -specific receptors for E series of prostaglandins (EP receptors) abrogated the angiogenic effect of the CM (supplementary Figure 4 is available at Carcinogenesis Online), suggesting that PGE 2 is essentially involved in the COX-2-mediated angiogenesis. Our results are in agreement with previous reports demonstrating that PGE 2 may promote angiogenesis via activating various molecular signalings through EP receptors in the endothelium (40, 41) . Recently, analysis of BM specimens from acute leukemia patients demonstrated increased expression of VEGF-C and its receptor, VEGF-R3, in leukemic blasts (21), suggesting an angiogenic autocrine loop involving VEGF-C/VEGF-R3 for BM angiogenesis of patients with leukemia. Additionally, previous reports have shown that endothelial cells produce VEGF-C, particularly in response to pro-inflammatory cytokines, such as interleukin-1 and tumor necrosis factor. VEGF-C, in turn, may support leukemic survival and proliferation and protect VEGF-R3 þ leukemias from chemotherapy-induced apoptosis (18) . In this paradigm, the results of the current study further suggest the existence of a novel angiogenic paracrine loop involving the VEGF-C/VEGF-R3/COX-2 pathway in leukemic cells, which may contribute to the progression of a subset of leukemias.
Transcriptional activation of COX-2 occurs quickly and transiently in response to a wide range of stimuli, including pathogens, cytokines, nitric oxide, irradiation, growth factors and various extracellular ligands (42) . The induction of COX-2 by VEGF-C in leukemic cells was mediated by activation of the VEGF-R3/JNK/AP-1 pathway. It is already known that VEGF-R2 activation can induce upregulation of COX-2 via p38 MAPK-and JNK-signaling pathways in human vascular endothelial cells (43) . In line with this study, VEGF-A can also induce upregulation of COX-2 in leukemic cells (supplementary Figure 3B is available at Carcinogenesis Online). However, several observations support a critical role for VEGF-R3 in VEGF-Cmediated induction of COX-2. Exposure of leukemic cells with wild-type VEGF-C or the VEGF-R3-selective mutant of VEGF-C (Cys156Ser mutation) induced comparable levels of COX-2. Treatment of leukemic cells with recombinant soluble VEGF-R3/Fc, which can block ligand binding to VEGF-R3, abrogated VEGF-C-mediated induction of COX-2. Clinically, expression of VEGF-C and COX-2 are correlated in BM specimens from patients with AML (Table I) , suggesting a crucial role of VEGF-R3-mediated signaling in regulation of COX-2 in leukemic cells.
In lymphatic cells, activation of VEGF-R3 by VEGF-C induces proliferation, migration and survival, and it has been shown to activate the classic signaling, ERK1/2 and AKT (6). In THP-1 cells, however, these two downstream signal cascades were not involved in VEGF-Cinduced COX-2 expression. Several lines of evidence suggest that VEGF-C induced COX-2 via activation of JNK. First, VEGF-C stimulates JNK activation in THP-1 cells. Second, the chemical inhibitor or dominant-negative mutant of JNK suppressed VEGF-C-induced COX-2 expression in THP-1 cells. These findings are in line with previous evidence showing that activation of JNK by VEGF-A was linked to increased COX-2 transcription in vascular endothelial cells (43) . Besides, phosphorylation of tyrosine 1063 on VEGF-R3 induces a survival signaling cascade, including CRKI/II recruitment to the receptor, and further induces JNK activation (34) . Further studies are therefore needed to determine whether phosphorylation of tyrosine 1063 on VEGF-R3 is involved in the regulation of COX-2 by VEGF-C in leukemic cells.
The 5#-untranslated region of the COX-2 gene contains binding sites for numerous regulatory transcription factors, including NF-jB, NF-IL-6-binding elements and CRE, among others (44) . Our promoter luciferase assay demonstrated the participation of CRE, but not NF-jB or NF-IL-6-binding elements, in regulating VEGF-C-induced COX-2 transcription. Numerous studies have indicated that NF-jB plays an important role in the regulation of COX-2 expression in cancer cells (45) . Interestingly, our present data showed that mutations in the NF-jB-binding site unchanged VEGF-C-induced COX-2 promoter activity. NF-jB inhibitor also did not suppress COX-2 expression induced by VEGF-C. Moreover, VEGF-C did not induce NF-jB subunit, p65, nuclear translocation (data not shown). The involvement of CRE in COX-2 expression has been reported in tumor cells stimulated with oncogenic protein or nitric oxide (46, 47) . Typically, cyclic adenosine 3#,5#-monophosphate-response element binding protein-1, activating transcription factor-1, c-jun, c-fos and activating transcription factor-2, 
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which belong to the AP-1 family, are associated with the CRE site (48, 49) . Our results showed that VEGF-C induced the AP-1 subunit, c-jun, but not c-fos, nuclear translocation. The functional importance of AP-1 was established because VEGF-C-mediated activation of the COX-2 promoter was suppressed by mutagen-induced changes in the CRE sites. This result was confirmed by ChIP analysis. Collectively, these finding suggest that AP-1/CRE is a major modulator of VEGF-Cinduced COX-2 expression in leukemic cells. The present report is the first demonstration that VEGF-C, by acting in an autocrine/paracrine fashion, may actually contribute to tumor angiogenesis by induction of COX-2/prostanoids in subsets of leukemia. We have shown significant induction of VEGF-C by COX-2 in other context (50) . Hence, the cross talk between VEGF-C and COX-2 might initiate a positive feedback loop, resulting in enhanced expression of COX-2 and increased synthesis of prostanoids, which lead in turn to a further increase in VEGF-C activity. Supplementary Figures 1-5 and Table 1 can be found at http:// carcin.oxfordjournals.org/
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